Universal Beteiligungs und Servicegesellschaft mbH Trims Stake in Insmed, Inc. $INSM

Universal Beteiligungs und Servicegesellschaft mbH cut its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 36.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 54,529 shares of the biopharmaceutical company’s stock after selling 31,864 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Insmed were worth $7,853,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Spire Wealth Management increased its position in Insmed by 11.5% in the third quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 80 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in shares of Insmed by 59.6% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 81 shares during the period. Moody Aldrich Partners LLC grew its stake in shares of Insmed by 2.4% during the 3rd quarter. Moody Aldrich Partners LLC now owns 5,551 shares of the biopharmaceutical company’s stock valued at $799,000 after acquiring an additional 132 shares during the period. First Horizon Advisors Inc. increased its holdings in Insmed by 24.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 186 shares in the last quarter. Finally, Yousif Capital Management LLC raised its stake in Insmed by 9.3% during the 3rd quarter. Yousif Capital Management LLC now owns 2,188 shares of the biopharmaceutical company’s stock worth $315,000 after acquiring an additional 187 shares during the period.

Insider Transactions at Insmed

In other Insmed news, COO Roger Adsett sold 2,059 shares of Insmed stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $174.17, for a total value of $358,616.03. Following the sale, the chief operating officer owned 107,601 shares of the company’s stock, valued at $18,740,866.17. The trade was a 1.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $158.93, for a total value of $1,700,392.07. Following the sale, the chief executive officer directly owned 306,891 shares in the company, valued at $48,774,186.63. This trade represents a 3.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 296,799 shares of company stock valued at $54,296,286. 3.00% of the stock is owned by company insiders.

Analyst Ratings Changes

INSM has been the topic of several analyst reports. Rothschild Redb raised shares of Insmed to a “strong-buy” rating in a report on Thursday, December 4th. Redburn Partners set a $263.00 price objective on shares of Insmed in a research report on Thursday, December 4th. Royal Bank Of Canada lifted their target price on shares of Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a research note on Wednesday. Mizuho set a $212.00 target price on shares of Insmed in a report on Thursday, December 18th. Finally, Bank of America raised their price target on Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a report on Monday, October 27th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $204.68.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $156.21 on Monday. The firm has a market cap of $33.31 billion, a price-to-earnings ratio of -25.24 and a beta of 1.08. The firm has a fifty day moving average price of $184.40 and a 200 day moving average price of $156.95. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $212.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. During the same quarter in the prior year, the firm posted ($1.27) earnings per share. The business’s revenue was up 52.4% on a year-over-year basis. As a group, sell-side analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.